CANF News & Events

Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs. Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals. Vetbiolix has exercised its option to enter into a full licensing agreement with Can-Fite and is responsible for all development and regulatory activities. Under the agreement, Can-Fite is entitled to receive upfront, milestone, and royalty payments, representing projected revenues of up to $325M over the next decade, subject to successful development and commercialization.

Can-Fite BioPharma announced that the Israeli Patent Office has allowed its patent application No. 284463, titled "An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect." The allowed patent covers the use of A3 adenosine receptor agonists, including the Company's lead drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders. This allowance represents a key addition to Can-Fite's expanding global intellectual property portfolio around Namodenoson's anti-obesity activity and follows similar patent advancements in other major jurisdictions including the US, Canada and Australia, strengthening the Company's worldwide protection strategy. Recently the technology granted scientific recognition upon coming up with a breakthrough publication of peer-reviewed study in the International Journal of Obesity, demonstrating the anti-obesity effect of namodenoson

Can-Fite BioPharma announced results from its Phase IIa open-label study evaluating namodenoson in patients with advanced pancreatic ductal adenocarcinoma who had progressed following prior systemic therapies. The study met its primary endpoint, which was safety, demonstrating that namodenoson was very well tolerated in this heavily pretreated patient population. No new safety signals were identified, and the safety profile was consistent with the known clinical experience of namodenoson in other oncological diseases. The study enrolled 20 patients with advanced PDAC who had received one or more prior lines of therapy. Patients represented a high-risk population, including individuals with varying performance status and advanced metastatic disease. Secondary endpoints included overall survival and progression-free survival. Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off. As follow-up continues, survival outcomes are expected to further mature and will be announced during upcoming scientific meetings.Namodenoson is a highly selective A3 adenosine receptor agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The drug is also being evaluated in clinical trials for advanced liver cancer. Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of pancreatic cancer.